Experimental data published on use of recommended medicines and treatments by UK's NHS
Experimental data about the use of the UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) recommended medicines and treatments by National Health Service organizations was yesterday published by the Health and Social Care Information Centre (HSCIC) on behalf of the Department of Health and the NHS Commissioning Board (NHS CB).
NICE Technology Appraisals in the NHS in England 2011; Experimental Statistics – Innovation Scorecard; follows the Innovation Health and Wealth paper published by the DoH in 2011, which set out plans to support development and adoption of innovation in the NHS.
The publication presents limited data at organizational level about the use of medicines and medical technologies recommended for use in the NHS in England by the NICE. It takes the form of an interactive spread-sheet and accompanying report, which describes the data and its limitations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze